Header Logo

Connection

MEENAKSHI HEGDE to Dose-Response Relationship, Drug

Back to Details
This is a "connection" page, showing publications MEENAKSHI HEGDE has written about Dose-Response Relationship, Drug.
MEENAKSHI HEGDE
Connection Strength
0.046
Dose-Response Relationship, Drug
  1. A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3-Expressing Relapsed or Refractory Solid Tumors. Cancer Res Commun. 2025 Sep 01; 5(9):1574-1583.
    View in: PubMed
    Score: 0.046
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.